BioCentury | May 19, 2017
Strategy

Contracting 2.0

...did so in the battle over the Sovaldi follow-ons: pitting the less convenient, lower cost Viekira Pak...
BioCentury | Dec 16, 2016
Company News

Harvoni sales and marketing update

...Viekira Pak ombitasvir/paritaprevir/ritonavir from AbbVie Inc. (NASDAQ:ABBV, Chicago, Ill.). Express Scripts will offer both Harvoni and Viekira Pak...
BioCentury | Dec 13, 2016
Company News

Express Scripts adds Harvoni, expands indication-based pricing

...an HCV pricing war, Harvoni had been kept out in favor of exclusive access for Viekira Pak...
...Inc. (NASDAQ:ABBV) (see BioCentury, Jan. 19, 2015) . Express Scripts will offer both Harvoni and Viekira Pak...
...control costs (see BioCentury, March 28) . The changes go into effect Jan. 1, 2017. Becky Simon Harvoni Viekira Pak AbbVie...
BioCentury | Oct 4, 2016
Company News

FDA adds warning to HCV drugs' labels

...Harvoni ledipasvir /sofosbuvir and Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD); Technivie ombitasvir/paritaprevir/ritonavir and Viekira Pak ombitasvir/paritaprevir/ritonavir plus dasabuvir...
BioCentury | Oct 3, 2016
Clinical News

Exviera dasabuvir: Phase IIIb data

...HCV genotype 1b infection in patients with and without compensated cirrhosis. In the U.S., AbbVie’s Viekira Pak...
BioCentury | Oct 3, 2016
Clinical News

Viekirax ombitasvir/paritaprevir/ritonavir: Phase IIIb data

...HCV genotype 1b infection in patients with and without compensated cirrhosis. In the U.S., AbbVie’s Viekira Pak...
BioCentury | Aug 8, 2016
Clinical News

Viekira XR ombitasvir/paritaprevir/ritonavir/dasabuvir regulatory update

...1a infection. The product is a once-daily, extended-release, co-formulation of the active ingredients in AbbVie’s Viekira Pak...
BioCentury | Aug 1, 2016
Politics & Policy

Express Scripts names 2017 exclusions, preferred drugs

...launches. AbbVie Inc. (NYSE:ABBV) has negotiated exclusive formulary status for its HCV therapies, including Viekira Pak ombitasvir/paritaprevir/ritonavir plus dasabuvir...
BioCentury | Jul 29, 2016
Company News

Humira buoys AbbVie as HCV market share shrinks

...particularly in public channels including the U.S. Department of Veterans Affairs . Sales of Viekira Pak ombitasvir/paritaprevir/ritonavir plus dasabuvir...
BioCentury | May 2, 2016
Analyst Picks & Changes

Analyst picks & changes

...Bayko downgraded after AbbVie Inc. (NYSE:ABBV) reported $414M in 1Q16 sales of HCV drug Viekira Pak ombitasvir/paritaprevir/ritonavir plus dasabuvir...
...$531M consensus estimate. Enanta, which developed paritaprevir with AbbVie, is eligible for royalties on U.S. Viekira Pak...
...newly launched HCV competitor Zepatier grazoprevir/elbasvir from Merck & Co. Inc. (NYSE:MRK) and lowered its Viekira Pak...
Items per page:
1 - 10 of 88